ProCE Banner Activity

My Thoughts on Immunotherapy and PD-L1 Testing in Metastatic Lung Adenocarcinoma

Clinical Thought
Are you considering immunotherapy for your patients with metastatic lung adenocarcinoma? Leora Horn, MD, MSc, FRCPC, shares her thoughts on the role of PD-L1 testing in selection of immune checkpoint inhibitors.

Released: July 08, 2016

Expiration: July 07, 2017

Share

Faculty

Leora Horn

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Boehringer Ingelheim

Genentech BioOncology

Lilly

Novartis Oncology

Faculty Disclosure

Primary Author

Leora Horn, MD, MSc

Assistant Professor, Hematology Oncology/Medicine
Vanderbilt Ingram Cancer Center
Vanderbilt University
Nashville, Tennessee

Leora Horn, MD, MSc, FRCPC, disclosed that she has received consulting fees from AbbVie, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Merck, and Xcovery.